Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
Passage Bio (NASDAQ: PASG) announced a conference call on March 6, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and recent business developments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Passage Bio (NASDAQ: PASG) announced a conference call on March 6, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and recent business developments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia. Through a collaboration with the University of Pennsylvania’s Gene Therapy Program, Passage Bio enhances its access to gene therapy candidates, leveraging its clinical and regulatory expertise. Investors can access the webcast on the company's website post-event.
Positive
- Strategic collaboration with the University of Pennsylvania enhances access to gene therapy candidates.
- Advancing clinical programs in significant CNS disorders.
Negative
- None.
Details
News Market Reaction – PASG
The recorded move for PASG in the trading session of this news was +7.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights.
To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia and our preclinical pipeline, including programs in amyotrophic lateral sclerosis and Huntington’s disease. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.